drugset

drugset / Trial / NCT00527410

A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis

NCT00527410 ↗

Phase 1 Terminated 9 enrolled Biogen

NaSingle-groupOpen-labelTreatment

Summary

This study assesses the tolerability, safety, efficacy and pharmacokinetics of RTA 744 in recurrent neoplastic meningitis.

Timeline

Start: 2006-10-31
Primary completion: 2008-12-01
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Berubicin	Small molecule	1 mg/ml	Intravenous

Indications